当前位置：首页 JCRQ3 期刊介绍(非官网)

European Journal Of Clinical Pharmacology

SCIE

国际简称：EUR J CLIN PHARMACOL 参考译名：欧洲临床药理学杂志

中科院分区
3区
CiteScore分区
Q2
JCR分区
Q3

基本信息：: ISSN：0031-6970; E-ISSN：1432-1041; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：GERMANY; 出版商：Springer Berlin Heidelberg; 出版语言：English; 出版周期：Monthly; 出版年份：1968; 研究方向：医学-药学

评价信息：: 影响因子：2.4; H-index：99; CiteScore指数：5.4; SJR指数：0.727; SNIP指数：0.99

发文数据：: Gold OA文章占比：32.62%; 研究类文章占比：70.59%; 年发文量：153; 自引率：0.0344...; 开源占比：0.3214; 出版撤稿占比：0; 出版国人文章占比：0.07; OA被引用占比：0.2584...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介European Journal Of Clinical Pharmacology期刊介绍

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

期刊简介European Journal Of Clinical Pharmacology期刊介绍

《European Journal Of Clinical Pharmacology》自1968出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：一般,3-8周
医学
PHARMACOLOGY & PHARMACY
SCIE
中科院3区
非预警

Cite Score数据（2024年最新版）European Journal Of Clinical Pharmacology Cite Score数据

CiteScore：5.4
SJR：0.727
SNIP：0.99

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q2	92 / 272	66%
大类：Medicine 小类：Pharmacology	Q2	142 / 313	54%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区European Journal Of Clinical Pharmacology 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	3区	PHARMACOLOGY & PHARMACY 药学	3区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区European Journal Of Clinical Pharmacology JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	188 / 354	47%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	192 / 354	45.9%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
France103
Spain94
CHINA MAINLAND93
Netherlands86
GERMANY (FED REP GER)77
USA77
Sweden76
Italy56
Japan56
England48

本刊中国学者近年发表论文

1、The pharmacokinetics and safety of lidocaine in liver cancer patients undergoing hepatic resection
Author: He, Chaoqun; Jin, Ying; Zhang, Yang; Zhang, Mengyu; Di, Xiangjie; Fu, Lisha; Qi, Xiaohui; Liu, Runhan; Zheng, Li; Wang, Zhenlei; Li, Jingdong; Tu, Faping

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s00228-023-03498-0
2、Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis
Author: Ma, Shaodi; Qu, Guangbo; Sun, Chenyu; Liu, Haixia; Jiang, Yuemeng; Li, Ning; Wu, Birong; Gao, Juan; Feng, Linya; Xie, Peng; Xia, Weihang; Kim, Na Hyun; Lowe, Scott; Bentley, Rachel; Zhu, Yike; Zhou, Qin; Sun, Yehuan

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 39-61. DOI: 10.1007/s00228-022-03414-y
3、Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis
Author: Hou, Xiaowen; Cen, Kaiwen; Cui, Ying; Zhang, Yuhong; Feng, Xu

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 63-70. DOI: 10.1007/s00228-022-03413-z
4、The risk of congenital heart defects associated with corticosteroids use during the first trimester of pregnancy: a systematic review and meta-analysis
Author: Wei, Jiehua; Xia, Fan; Miao, Junxiang; Wang, Tingting; Chen, Lizhang; Yan, Xuemei

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 1-11. DOI: 10.1007/s00228-022-03416-w
5、A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure
Author: Liao, Ru; Dong, Yalin; Chen, Lihong; Wang, Taotao; Li, Houli; Dong, Haiyan

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 149-157. DOI: 10.1007/s00228-022-03427-7
6、Reliability and feasibility of home-based dried blood spot in therapeutic drug monitoring: a systematic review and meta-analysis
Author: Xiaoyong, Xu; Xilin, Ge; Guangfei, Wang; Wei, Wu; Xiaowen, Zhai; Hong, Xu; Huimin, Zhang; Zhiping, Li

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 2, pp. 183-193. DOI: 10.1007/s00228-022-03417-9
7、Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials
Author: Sun, Yingchao; Yue, Lei; Hu, Weiling

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 2, pp. 279-288. DOI: 10.1007/s00228-022-03430-y
8、Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis
Author: Li, Xujia; Huang, Jinsheng; Jiang, Chang; Chen, Ping; Quan, Qi; Jiang, Qi; Li, Shengping; Guo, Guifang

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 3, pp. 323-340. DOI: 10.1007/s00228-022-03441-9